注意差距 - 在前进性和临床阿尔茨海默氏症的甲状腺间粘附
Gonzalo Forno1, Julie P Vidal2, Phoebe Rush3
1Geroscience Center for Brain Health and Metabolism (GERO), Santiago, Chile; Neuropsychology and Clinical Neuroscience Laboratory (LANNEC), Physiopathology Department - ICBM, Neuroscience and East Neuroscience Departments, Faculty of Medicine, University of Chile, Avenida Salvador 486, Providencia, Santiago, Chile.
Brain research bulletin
|September 25, 2025
概括
在阿尔茨海默氏病 (AD) 阶段,体间粘附 (IA) 并不比阿尔茨海默氏病 (AD) 更常见. 然而,一个广泛的IA亚型与更高的Aβ42和p-Tau水平有关,这表明它在早期AD中发挥了作用.
科学领域:
- 神经解剖学是一个神经解剖学.
- 神经退行性疾病 神经退行性疾病
背景情况:
- thalamus间粘附 (IA) 连接左侧和右侧的thalamus.
- 之前关于IA患病率和功能的研究排除了阿尔茨海默病 (AD).
研究的目的:
- 分析阿尔茨海默病神经成像倡议 (ADNI) 连续的AI患病率.
- 评估IA和AD脑脊液 (CSF) 生物标志物和大脑体积之间的关联.
主要方法:
- 从542名参与者 (健康对照,EMCI,LMCI,AD) 的MRI扫描中分析了IA患病率.
- 包括后勤回归在内的统计分析检查了IA,CSF生物标志物和体积之间的关系.
主要成果:
- 在AD连续组之间没有发现IA患病率或IA变异的显著差异.
- 单一IA是最常见的变种.
- 后期分析显示,在健康对照组和早期的MCI中,AD CSF生物标志物与广泛的IA亚型之间存在关联.
结论:
- 整体IA患病率在前期或临床AD方面没有差异.
- 升高的Aβ42和p-Tau,以及更大的乳头体积,与更高的广IA的可能性相关.
- 这些发现表明IA在早期阿尔茨海默病病理生理学方面的潜在参与.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
470
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
470
Amyloid Fibrils
11.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.6K


